

DR. CALEIGH FINDLEY (Orcid ID : 0000-0002-8759-1661)

Article type : Original Article

Riluzole Attenuates Glutamatergic Tone and Cognitive Decline in A β PP/PS1 Mice.

Kevin N. Hascup^{1-3†}, Caleigh A. Findley^{1-2†}, Jesse Britz², Nahayo Esperant-Hilaire¹, Sarah O. Broderick¹, Kristin Delfino⁴, Shelley Tischkau²⁻³, Andrzej Bartke^{3,5}, Erin R. Hascup^{1-2*}

¹Department of Neurology, Center for Alzheimer's Disease and Related Disorders, Neurosciences Institute, ²Department of Pharmacology, ³Department of Medical Microbiology, Immunology and Cell Biology, ⁴Department of Surgery, Center for Clinical Research, ⁵Department of Internal Medicine, Southern Illinois University School of Medicine, Springfield, IL, USA

[†]Authors contributed equally to the manuscript.

*Corresponding author: Hascup, ER, Department of Neurology, Center for Alzheimer's Disease and Related Disorders, Southern Illinois University School of Medicine, P.O. Box 19628, Springfield, IL 62794-9628, USA, Tel: 217-545-6988; Email: ehascup@siu.edu

Running head: Early Treatment with Riluzole in A β PP/PS1 Mice

Keywords: amyloid-beta (A β), Alzheimer's disease (AD), alpha-7 nicotinic acetylcholine receptor (α 7nAChR), prodromal intervention, biosensor, learning and memory

Abbreviations: alpha 7 nicotinic receptor (α 7nAChR), Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), beta amyloid (A β), bovine serum albumin (BSA), corrected integrated path length (CIPL), dopamine hydrochloride (DA), Fast Analytical Sensing Technology (FAST),

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/jnc.15224](https://doi.org/10.1111/jnc.15224)

This article is protected by copyright. All rights reserved

Accepted Article

glial fibrillary acidic protein (GFAP), glutamate transporter-1 (GLT-1), glutamate/glutamine (Glu/Gln), hydrogen peroxide (H₂O₂), L-ascorbic acid (AA), Morris water maze (MWM), N-methyl-D-aspartate (NMDA), phosphate-buffered saline (PBS), potassium chloride (KCl)

Abstract

We have previously demonstrated hippocampal hyperglutamatergic signaling occurs prior to plaque accumulation in A β PP/PS1 mice. Here, we evaluate 2-Amino-6-(trifluoromethoxy) benzothiazole (riluzole) as an early intervention strategy for AD, aimed at restoring glutamate neurotransmission prior to substantial A β plaque accumulation and cognitive decline. Male A β PP/PS1 mice, a model of progressive cerebral amyloidosis, were treated with riluzole from 2-6 months of age. Morris water maze (MWM), *in vivo* electrochemistry, and immunofluorescence were performed to assess cognition, glutamatergic neurotransmission, and pathology, respectively, at 12 months. Four months of prodromal riluzole treatment in A β PP/PS1 mice resulted in long-lasting procognitive effects and attenuated glutamatergic tone that was observed six months after discontinuing riluzole treatment. Riluzole-treated A β PP/PS1 mice had significant improvement in long-term memory compared to vehicle-treated A β PP/PS1 mice that was similar to normal aging C57BL/6J control mice. Further, basal glutamate concentration and evoked-glutamate release levels, which were elevated in vehicle-treated A β PP/PS1 mice, were restored to levels observed in age-matched C57BL/6J mice in A β PP/PS1 mice receiving prodromal riluzole treatment. Beta amyloid (A β) plaque accumulation was not altered with riluzole treatment. This study supports that interventions targeting the glutamatergic system during the early stages of AD progression have long-term effects on disease outcome, and importantly may prevent cognitive decline. Our observations provide preclinical support for targeting glutamate neurotransmission in patients at risk for developing AD.

Introduction

Alzheimer's disease (AD) is an age-related neurodegenerative disorder resulting in a gradual buildup of A β plaques and neurofibrillary tangles followed by hippocampal atrophy and progressive dementia (Jack *et al.* 2013; Mota *et al.* 2014). Current pharmacotherapy options include cholinesterase inhibitors aimed at increasing acetylcholine levels and preventing glutamate-induced excitotoxicity through N-methyl-D-aspartate (NMDA) receptor antagonism (Godyń *et al.* 2016). However, these therapies have limited efficacy, are symptomatic, and do not decelerate disease progression, which may be a consequence of administration at advanced AD stages when synapse loss is extensive. To slow or stop AD progression, it may be necessary to target neurological components that are altered during the prodromal phase of AD. Increasing evidence supports the glutamatergic system as a possible early target that meets these criteria (Paula-Lima *et al.* 2013; Minkeviciene *et al.* 2008; Hascup *et al.* 2019; Hascup *et al.* 2020).

Alterations to glutamate release and clearance may lead to the cognitive and functional decline observed in AD (Hascup *et al.* 2019; Hunsberger *et al.* 2015; Miller *et al.* 2008; O'Brien *et al.* 2010; Hascup *et al.* 2020). A prevailing hypothesis in AD research supports persistent, excessive activation of NMDA receptors impedes the detection of physiological signals and initiating cognitive impairment (Parsons *et al.* 2007; Parameshwaran *et al.* 2008; Olney *et al.* 1997; Winblad and Poritis 1999; Talantova *et al.* 2013). Several studies have observed hippocampal hyperactivity in mild cognitively impaired patients (Huijbers *et al.* 2015; Miller *et al.* 2008; O'Brien *et al.* 2010), particularly those with a familial history of AD (Okonkwo *et al.* 2014) and elevated amyloid-beta (A β) deposition (Huijbers *et al.* 2015), that is associated with increased severity of cognitive decline (Huijbers *et al.* 2015; O'Brien *et al.* 2010; Miller *et al.* 2008). Previous data support that accumulation of soluble A β isoforms underlie synaptic dysfunction and eventual neurodegeneration (Yang *et al.* 2017). Our laboratory and others have demonstrated that soluble A β_{42} elicits glutamate release through the alpha-7 nicotinic acetylcholine receptor ($\alpha 7$ nAChR) (Hascup and Hascup 2016; Mura *et al.* 2012; Talantova *et al.* 2013), which may contribute to elevated levels of hippocampal glutamate first observed prior to cognitive decline in double transgenic mice expressing the amyloid precursor protein (Mo/HuAPP695swe) and Presenilin 1 (PS1-dE9) genes (A β PP/PS1). Further, we have also reported subregion and age specific alterations in hippocampal glutamatergic activity in A β PP/PS1. Elevated dentate (DG) and CA1 evoked glutamate release is observed at 2-4 months of age, while elevated basal glutamate is observed in these regions by 6 months of age (Hascup *et al.* 2020). These

elevated levels continue to 12 months of age (Hascup *et al.* 2018; Hascup *et al.* 2019), when cognitive deficits are more pronounced. These findings indicate early alterations to the glutamatergic system evolve throughout disease progression as in A β PP/PS1 mice. Further, it supports the hypothesis that elevation of synaptic glutamate levels over time may result in excitotoxicity and eventual hippocampal atrophy observed in AD.

Attenuating glutamatergic tone by targeting glutamate release and uptake may provide promising therapeutic interventions for early AD. One possible intervention is 2-Amino-6-(trifluoromethoxy) benzothiazole (riluzole), which is thought to inhibit presynaptic excitation (Bellingham and Walmsley 1999; Ireland *et al.* 2004) and glutamate release (Wang *et al.* 2004; Bellingham 2011), while also restoring transporter expression and activity (Frizzo *et al.* 2004; Fumagalli *et al.* 2008; Carbone *et al.* 2012a). Further, riluzole has previously shown to attenuate A β_{42} -mediated increases in CA1 spike frequency and restore the DG excitatory / inhibitory imbalance resulting in improved cognitive performance (Yang *et al.* 2020; Ren *et al.* 2015). Based on these previous studies, we hypothesized that riluzole treatment has long-term procognitive benefits mediated by reducing the glutamatergic tone in amyloidogenic AD mice.

In this study, A β PP/PS1 mice were treated with riluzole (2-6 months of age) prior to the onset of cognitive deficits (Webster *et al.* 2014; Minkeviciene *et al.* 2008). Starting at 12 months of age, mice underwent Morris water maze (MWM) spatial learning and memory paradigm to assess cognition. This experimental design emphasizes a preventative approach to ameliorating the glutamatergic dyshomeostasis and cognitive decline observed at 12 months of age in this mouse model (Webster *et al.* 2014; Minkeviciene *et al.* 2008; Hascup *et al.* 2018; Hascup *et al.* 2019). *In vivo* hippocampal glutamate signaling was assessed using constant potential amperometry followed by immunofluorescence to examine hippocampal A β plaque burden and expression of several glutamatergic synaptic factors. The results presented here support that prodromal riluzole treatment has long-term procognitive efficacy by reducing hippocampal glutamatergic tone.

Methods

Animals: Male C57BL/6J (RRID:IMSR_JAX:000664) and A β PP/PS1 (RRID:MMRRC_034832-JAX) mice were obtained from Jackson Laboratory (Bar Harbor, ME). Protocols for animal use were approved by the *Laboratory Animal Care and Use Committee* at Southern Illinois University School of Medicine (Protocol #219-13-012) and the study was not pre-registered. Mice were group-housed on a 12:12 hour light: dark cycle, and food and water were available *ad libitum*. All experiments were conducted during the light phase. A timeline of the experimental design is presented in Figure 1. From 2-6 months of age, a randomly assigned cohort of A β PP/PS1 mice was given riluzole in the drinking water (12.5 mg/kg b.w./day in 1% sucrose; n=11). C57BL/6J (n=14) and the other cohort of A β PP/PS1 (n=12) mice were given 1% sucrose in the drinking water as vehicle control. Three mouse cages were pseudo-randomized using the Microsoft Excel randomization function to generate random decimal numbers between 0 and 1 for each cage and treatment. The dosing strategy was based on previously published studies using riluzole *in vivo* (Gourley *et al.* 2011; Ishiyama *et al.* 2004; Hunsberger *et al.* 2015). No exclusion criteria were pre-determined. All mice underwent cognitive assessment, *in vivo* glutamate recordings, and immunofluorescent analysis except for one C57BL/6J vehicle mouse was not used for glutamate measures because it died due to surgical complications and 3 mice (1 C57BL/6J vehicle and 2 A β PP/PS1 riluzole) were excluded from immunofluorescence because of inadequate sectioning or staining. Immediately following anesthetized glutamate recordings, mice were euthanized with an overdose of isoflurane followed by rapid decapitation. A 5 mm tail snip was sent to TransnetYX[®], Inc (Cordova, TN) to confirm genotypes. All mice were tattooed with unique numerical identifiers to blind researchers throughout experimental paradigms.

Chemicals: All chemicals were prepared and stored according to manufacturer recommendations unless otherwise noted. L-glutamate oxidase (EC 1.4.3.11) was obtained from Cosmo Bio Co. (Carlsbad, CA, USA; Cat: YMS-80049) and diluted in distilled, deionized water to make a 1U/ μ l stock solution for storage at 4°C. Sodium phosphate monobasic monohydrate (Cat: BP330-500), sodium phosphate dibasic anhydrous (Cat: S375-500), 1,3 phenylenediamine dihydrochloride (mPD; Cat: P017225G), sodium chloride (Cat: S271- 3), calcium chloride dehydrate (Cat: BP510-100), sucrose (Cat: 12-550-15), 30% hydrogen peroxide (H₂O₂) in water (Cat: H325-100), and riluzole (Cat: 1744-22-5) were obtained from Thermo Fisher Scientific (Waltham, MA). L-glutamic acid sodium salt (Cat: G1626), potassium chloride (KCl; Cat: P9333), bovine serum albumin (BSA; Cat: A3059),

glutaraldehyde (Cat: G5882), dopamine hydrochloride (DA; Cat: H8502), and L-ascorbic acid (AA; Cat: A7056) were obtained from Sigma-Aldrich Co. (St. Louis, MO, USA). Chicken polyclonal glial fibrillary acidic protein (GFAP) primary antibody (RRID:AB_2492333) and Amylo-Glo® RTD™ (Cat: TR-300-AG) was obtained from Biosensis (Temecula, CA). Rabbit polyclonal primary antibody α 7nAChR was obtained from Alomone Labs (Jerusalem, Israel; RRID:AB_10659339).

Morris Water Maze (MWM) Training and Probe Challenge: At approximately 12 months of age, mice underwent cognitive assessment using the MWM spatial learning and memory recall paradigm. The MWM tests spatial learning and memory by requiring the mouse to utilize visual cues to repeatedly swim to a static, submerged platform (Bromley-Brits *et al.* 2011). The MWM paradigm consisted of 5 consecutive learning days with three, 90-sec trials/day and a minimum inter-trial interval of 20 minutes. After two days without testing, mice are given a single, 60-sec probe challenge to test long-term memory recall. The ANY-maze video tracking system (Stoelting Co., Wood Dale, IL; RRID:SCR_014289) was used to record navigational parameters and data analysis. The three trials for each training day were averaged for each mouse for analysis. Variables extracted from ANY-maze and utilized for data analysis include swimming speed, platform cumulative distance, platform corrected integrated path length, percent time in quadrant, and annulus 40 entries.

Enzyme-Based Microelectrode Arrays: Enzyme-based MEAs were fabricated, assembled, coated, and calibrated for *in vivo* glutamate measurements as previously described (Hascup *et al.* 2016; Hascup and Hascup 2015; Hascup and Hascup 2016; Hascup *et al.* 2019; Hascup *et al.* 2018). One of the R2 MEA Pt sites was coated with L-glutamate oxidase solution [containing BSA and glutaraldehyde for enzyme adhesion] to enzymatically degrade glutamate to α -ketoglutarate and H_2O_2 , the electroactive reporter molecule. The second Pt recording site (self-referencing or sentinel site) was coated with a BSA and glutaraldehyde solution, which is unable to enzymatically generate H_2O_2 from L-glutamate. A potential of +0.7V vs a Ag/AgCl reference electrode was applied to the Pt recording surfaces resulting in oxidation of the H_2O_2 reporter molecule. The subsequent current generated from the two-electron transfer was amplified and digitized by the Fast Analytical Sensing Technology (FAST) 16mkIII (Quanteon, LLC; Nicholasville, KY) electrochemistry instrument.

mPD Electropolymerization: After enzyme coating, all Pt recording surfaces were electroplated with 5 mM mPD in 0.05 M phosphate-buffered saline (PBS). FAST electroplating software applied a triangular wave potential with an offset of -0.5 V, peak-to-peak amplitude of 0.25 V, at a frequency of

0.05 Hz, for 20 min. This created a size exclusion layer that restricts the passage of AA, DA, uric acid, and 3,4-dihydroxyphenylacetic acid to the Pt recording surface (Hascup *et al.* 2016).

Calibration: Each MEA underwent an *in vitro* calibration prior to implantation to create a standard curve for the conversion of current to glutamate concentration. The Pt recording sites and a glass Ag/AgCl reference electrode (Bioanalytical Systems, Inc., West Lafayette, IN) were placed in a continuously stirred solution of 40.0 mL of 0.05 M PBS maintained at 37°C with a recirculating water bath (Stryker Corp., Kalamazoo, MI). Final beaker concentrations of 250 μ M AA, 10, 20, 30, and 40 μ M L-glutamate, 2 μ M DA, and 8.8 μ M H₂O₂ were used to assess MEA performance. Thirty-eight MEAs were used with an average $\pm$ standard error of the mean (SEM) for glutamate sensitivity of 6.0 $\pm$ 0.1 pA/ μ M ($r^2 = 0.998 \pm 0.001$), selectivity ratio of 391 $\pm$ 46 to 1, and limit of detection of 0.2 $\pm$ 0.02 μ M based on a signal-to-noise ratio of 3. A glass micropipette (World Precision Instruments, Inc., Sarasota, FL) was attached to the MEA and used to locally apply 70 mM KCl (isotonic; pH 7.4) to the mouse hippocampal subfields (Hascup *et al.* 2016; Hascup and Hascup 2015; Hascup *et al.* 2019; Hascup *et al.* 2018). The fluid was pressure-ejected using a Picospritzer III (Parker-Hannafin, Cleveland, OH), with pressure (5-15 psi) adjusted to deliver consistent volumes over 1-2 second intervals and monitored with a stereomicroscope (Luxo Corp., Elmsford, NY) fitted with a calibrated reticule.

In Vivo Anesthetized Recordings: Beginning one week after MWM, mice were anesthetized using 1.5-2.0% isoflurane (Abbott Lab, North Chicago, IL) in a calibrated vaporizer (Vaporizer Sales & Service, Inc., Rockmart, GA) and prepared for *in vivo* electrochemical recordings (Hascup *et al.* 2016; Hascup *et al.* 2019; Hascup *et al.* 2018). A Ag/AgCl reference wire was subdurally positioned above the right cortex. For each mouse, the MEA / micropipette assembly was lowered into the DG (AP: -2.0, ML: $\pm$ 1.0, DV: -2.2 mm), CA3 (AP: -2.0, ML: $\pm$ 2.0, DV: -2.2 mm), and CA1 (AP: -2.0, ML: $\pm$ 1.0, DV: -1.7 mm), from Bregma (Paxinos and Franklin 2004) that was randomly assigned. Constant voltage amperometry (4 Hz) was performed by using a potential of +0.7 V vs the Ag/AgCl reference electrode applied by the FAST16mkIII electrochemical instrument (Quanteon LLC; Nicholasville, KY). MEAs were allowed to reach a stable baseline for 60 min before a 10-second basal glutamate determination and pressure ejection studies commenced. The FAST software saves amperometric data, time and pressure ejection events for all recording sites. Calibration data, in conjunction with a MATLAB (MathWorks, Natick, MA) graphic user interface program was used to calculate basal glutamate and stimulus-evoked glutamate release and uptake. Five reproducible

signals were evoked in each hippocampal subfield and averaged into a representative signal for treatment comparisons.

Immunodetection, Amyloid Plaque Staining, and Semiquantification: Immediately following *in vivo* glutamate measurements, brains were fixed in 4% paraformaldehyde for 48 hrs and then transferred into 30% sucrose in 0.1M phosphate buffer for 24 hours prior to sectioning (Hascup *et al.* 2016; Hascup *et al.* 2019; Hascup *et al.* 2018). Primary antibodies were applied to every sixth section (20 μ m thickness) from the hippocampus at the following concentrations: chicken polyclonal GFAP antibody (Biosensis; 1:100) or rabbit polyclonal α 7nAChR antibody (Alomone Labs; 1:200). Slides were treated with 10% H₂O₂ in 20% methanol for 10 min and then transferred to a 70% ethanol solution for 5 min followed by a 2 min wash in PBS. Sections were incubated for 10 min in 1X Amylo-Glo[®] RTD[™] and rinsed in 0.9% saline for 5 minutes without shaking followed by rinsing (3 x 2 min) in PBS. Sections were permeabilized in PBS with 0.25% TritonX-100 (PBST) followed by washes (3 x 10 min) in sodium borohydride in PBS (1 mg/ml) for antigen retrieval. To control for nonspecific binding, sections were washed (3 x 10 min) with PBST and incubated in 10% normal goat serum for 1 hour followed by overnight incubation (4°C) with primary antibody. The next day, sections were washed (3 x 10 min) in PBST and incubated at room temperature for 1 hr with either AlexaFlour 594 goat anti-chicken (ThermoFisher Scientific; 1:1000; RRID:AB_2534099) or AlexFlour 594 goat anti-rabbit (ThermoFischer Scientific; 1:1000, RRID:AB_2534079), respectively. Afterward, sections were washed (3 x 10 min) in PBST and coverslipped using Fluoromount-G (SouthernBiotech; Birmingham, AL) either with DAPI (α 7nAChR) or without DAPI (GFAP/A β). To control for staining intensity, all sections were allowed to develop overnight and imaged the following day. Staining intensity was determined using National Institutes of Health Image J Software (v. 1.48; RRID:SCR_003070) to measure a grayscale value within the range of 0–256, where 0 represents white and 256 represents black. Individual templates at two magnifications (10x for GFAP/A β ; 40x for α 7nAChR/DAPI) for the DG, CA3, and CA1 were created and used on all brains similarly. Images were captured with an Olympus 1x71 microscope equipped with an Olympus-DP73 video camera system, and a Dell Optiplex 7020 computer. Measurements were performed blinded, and approximately four sections per subregion (DG, CA3, and CA1) were averaged to obtain one value per subject. Amyloid plaques were identified by a dense spherical core of intense staining that were often surrounded by a less compact spherical halo. Staining density was obtained when background

staining was subtracted from mean staining intensities on every sixth section through the hippocampus.

Data Analysis: Sample size was determined based on previous MWM, electrochemical, and immunofluorescence data using C57BL/6J and A β PP/PS1 mice. A power calculation indicated a minimum of 10 mice per group for MWM and electrochemical recordings and five mice per group for immunofluorescent analysis (Hascup *et al.* 2018) to detect differences with 95% confidence (α = 0.05) and 0.8 power. Prism (GraphPad Software, Inc., La Jolla, CA; RRID: SCR_002798) software was used for statistical analyses. To determine if our data plan was appropriate for the collected data, the following assumptions were tested. Significant outliers were identified with a single Grubbs' test (α = 0.05) per group. Dependent variables were approximately normally distributed for each group of the independent variable as determined with the Anderson-Darling test as well as visual quantile-quantile plots. A Brown-Forsythe test indicated homogeneity of variances was reasonably met allowing us to proceed with our statistical tests. MWM trial days were analyzed with a two-way ANOVA while the MWM probe challenge, glutamate recordings, and immunofluorescent semiquantification was analyzed with a one-way ANOVA. When the ANOVA indicated a statistically significant main effect, a Dunnett's post-hoc analysis was used to determine treatment differences against the A β PP/PS1 vehicle treated cohort. A two-tailed Student's t-test was used to compare amyloid plaques in both A β PP/PS1 cohorts. Hippocampal subregions were analyzed independently for glutamate recordings and immunofluorescent semiquantification. Data are represented as mean $\pm$ SEM and statistical significance was defined as $p < 0.05$.

Results

Riluzole Mouse Weights: Mice were weighed one week prior to starting treatment and then weekly until treatment completion and again during the MWM. Mice gained weight similarly (Table 1) and weight differences were not observed between treatment groups throughout the study ($F_{2,34}=0.28$, $P=0.75$) supporting that riluzole treatment did not cause nausea-like response.

Riluzole Cognitive Assessment: Six months post riluzole treatment, all mice underwent MWM testing. No differences in swim speed across treatment groups was observed on any training day (Figure 2A) indicating similar motor capabilities. A significant main effect over training days of the corrected integrated path length (CIPL) to the platform (Figure 2B; $F_{4,136}=17.20$, $P<0.0001$) and cumulative distance from the platform (Figure 2C; $F_{4,136}=16.46$, $P<0.0001$) was observed indicating all treatment groups successfully learned the location of the hidden escape platform. Additionally, a main effect of treatment groups was also observed for the CIPL to the platform ($F_{2,34}=10.99$, $P=0.0002$) and cumulative distance from the platform ($F_{2,34}=10.61$; $P=0.0003$). Post-hoc analysis indicated that A β PP/PS1 vehicle mice were slower to learn the location of the hidden escape platform compared to both C57BL/6J vehicle and A β PP/PS1 riluzole mice over the first 3 training days. No differences were observed over subsequent training days. Representative tracking plots of the 60-second probe challenge are shown in Figure 2D. During the probe challenge, swim speed was consistent across treatment groups (Figure 2E) indicating differences in memory retention was not a result of motor performance. Analysis of the percentage of time spent in each quadrant indicate a main effect of quadrant occupancy in C57BL/6J vehicle ($F_{3,52}=15.43$, $P<0.0001$), A β PP/PS1 riluzole ($F_{3,40}=13.42$, $P<0.0001$), and A β PP/PS1 vehicle ($F_{3,44}=17.39$, $P<0.0001$). But a post-hoc analysis revealed that A β PP/PS1 vehicle mice were the only treatment group to not selectively search the target quadrant for the former location of the hidden escape platform during the probe challenge (Figure 2F). A main effect of the number of annulus 40 entries ($F_{2,34}=3.36$, $P=0.04$) was observed. Post-hoc analysis indicated that A β PP/PS1 vehicle mice entered the annulus 40 fewer times compared to C57BL/6J vehicle mice with a trend to improved performance after riluzole treatment (Figure 2G). These data support that 12-month-old A β PP/PS1 vehicle-treated mice have impaired cognition compared to age-matched C57BL/6J mice and that four months of riluzole treatment had long-lasting effects in its ability to rescue learning and memory deficits in A β PP/PS1 mice; similar to normal aging C57BL/6J mice.

Riluzole Glutamate Measures: Representative traces of stimulus-evoked glutamate release are shown in Figure 3A. A main effect on treatment group for basal glutamate (Figure 3B) was observed in the DG ($F_{2,33}=15.65$, $P<0.0001$), CA3 ($F_{2,33}=9.03$, $P=0.0007$), and CA1 ($F_{2,33}=13.97$, $P<0.0001$). A post-hoc analysis revealed that A β PP/PS1 vehicle hippocampal basal glutamate was significantly elevated compared to C57BL/6J vehicle and A β PP/PS1 riluzole mice. Similar volumes of 70 mM KCl (Figure 3C) were used to elicit glutamate release in the DG ($F_{2,33}=0.4905$, $P=0.61$), CA3 ($F_{2,33}=2.43$, $P=0.10$), and CA1 ($F_{2,33}=0.20$, $P=0.82$). A main effect of stimulus-evoked glutamate release (Figure 3D) was observed in the DG ($F_{2,33}=5.77$, $P=0.0071$), CA3 ($F_{2,33}=8.07$, $P=0.0014$) and CA1 ($F_{2,33}=13.87$, $P<0.0001$). Post-hoc analysis indicated that hippocampal glutamate release was increased in A β PP/PS1 vehicle-treated compared to both C57BL/6J vehicle- and A β PP/PS1 riluzole-treated mice. A main effect on the uptake rate of stimulus-evoked glutamate release (Figure 3E) was observed in the CA3 ($F_{2,33}=7.16$, $P=0.0026$) and CA1 ($F_{2,31}=5.05$, $P=0.0126$), but not the DG ($F_{2,33}=0.15$, $P=0.86$). A post hoc analysis indicates A β PP/PS1 vehicle mice have a faster glutamate uptake rate compared to both C57BL/6J vehicle and A β PP/PS1 riluzole treated mice in the CA3 and CA1. These data support that 12-month-old A β PP/PS1 mice have elevated basal glutamate and evoked glutamate release compared to age-matched C57BL/6J mice and that four months of riluzole treatment resulted in attenuated hippocampal glutamatergic tone in A β PP/PS1 mice; similar to levels observed in cognitively normal C57BL/6J mice.

Immunofluorescence:

$\alpha 7nAChR$

We previously reported that soluble A β_{42} interacts with presynaptic $\alpha 7nAChRs$ to stimulate glutamate release in the DG, CA1, and CA3 hippocampal subregions (Hascup and Hascup 2016). To determine if differences in stimulus-evoked glutamate release were a result of altered $\alpha 7nAChR$ density, we used immunofluorescence to measure changes in $\alpha 7nAChR$. The specificity of the $\alpha 7nAChR$ primary antibody has been previously demonstrated in $\alpha 7nAChR$ knockout mice (Nishio *et al.* 2017) and a negative control confirming its specificity in mouse hippocampal tissue is shown in Supplemental Figure 1. Representative images from the CA1 of C57BL/6J vehicle-, A β PP/PS1 vehicle-, and A β PP/PS1 riluzole-treated mice are shown (Figures 4A-I). We observed no significant differences in between treatment groups for each hippocampal subregion (DG: $F_{2,31}=1.263$, $P=0.1992$; CA1: $F_{2,31}=4.014$, $P=0.1068$; CA3: $F_{2,31}=3.465$, $P=0.0811$). Changes in glutamate

dynamics across treatment groups was not a result of $\alpha 7$ nAChR expression differences, thereby negating potential differences due to $A\beta_{42}$ -mediated glutamate release at these receptors.

GFAP and A β Plaques Staining

Immunofluorescence was used to measure changes in GFAP, while plaque pathology was determined using Amylo-Glo staining reagent. Representative images of C57BL/6J vehicle-, A β PP/PS1 vehicle-, and A β PP/PS1 riluzole-treated mice from the DG (Figure 5A-C; Top) and the CA1 / CA3 (Figure 5D-F; Bottom). Merged images highlight astroglial responses surrounding amyloid plaques in both cohorts of A β PP/PS1 mice. GFAP average mean densities for each hippocampal subfield are presented in Figure 5G. No differences in the average mean density of GFAP for each hippocampal subregion were observed, indicating differences in glutamate uptake rate are not attributed to astrocyte density (DG: $F_{2,30}=1.272$, $P=0.2951$; CA1: $F_{2,30}=0.1813$, $P=0.8351$; CA3: $F_{2,30}=0.4370$, $P=0.65$). The number of hippocampal amyloid plaques for both cohorts of A β PP/PS1 mice are shown in Figure 5H. Riluzole treatment had no effect on amyloid accumulation in the DG ($t_{19} = 0.2301$, $p = 0.82$), CA3 ($t_{19} = 0.4791$, $p = 0.64$), nor CA1 ($t_{19} = 0.2926$, $p = 0.77$).

Discussion

Riluzole is a Food and Drug Administration approved drug for the treatment of ALS and is undergoing a Phase II clinical trial for the treatment of mild AD (Clinical Trial #NCT01703117). Riluzole is known to target the glutamatergic system to achieve enhanced glutamate uptake and attenuate glutamate release. Elevated glutamate uptake may be due to improved function/activity of Na⁺-K⁺-ATPase (Deng *et al.* 2009), glutamate transporter-1 (Fumagalli *et al.* 2008), and the glutamate/glutamine (Glu/Gln) cycle (Deng *et al.* 2009). Immunofluorescent staining for Glt-1 indicated no differences across treatment groups (data not shown). This may indicate riluzole-mediated changes to the Glu/Gln cycle may be several-fold. First, evidence supports enhanced astrocytic glutamine synthetase with riluzole treatment (Deng *et al.* 2009), which breaks down glutamate to glutamine and may help to stimulate glutamate uptake. Glutamine shuttling from astrocytes to neurons is also increased with riluzole treatment (Chowdhury *et al.* 2008), however, riluzole also potentially inhibits the high-affinity glutamine transport system (Gln/ 2-(methylamino) isobutyrate) responsible for transporting glutamine into neurons (Erickson 2017), effectively decreasing the glutamine pool in neurons available to produce glutamate. This is further confounded by an increase in glutamate metabolism with more glutamate entering into the tricarboxylic acid cycle (Chowdhury *et al.* 2008). Together, these actions have a combined effect of increasing glutamate clearance and inhibiting glutamate release, yet it is unclear how long these metabolic actions persist after cessation of drug treatment or if there is a long-term effect on cognition.

We have previously shown that tight regulation of hippocampal glutamatergic signaling is involved in successful aging in a mouse model of longevity and improved healthspan (Hascup *et al.* 2015; Hascup *et al.* 2016), evoked glutamate release is increased in the CA1 of young (2-4 months old) A β PP/PS1 mice without detectable changes in basal glutamate levels (Hascup *et al.* 2020), and soluble A β_{42} , which is one of the earliest detectable biomarkers of AD (Jack *et al.* 2013), elicits glutamate release (Hascup and Hascup 2016). More recently, we determined that both evoked glutamate release and basal glutamate levels were elevated throughout the hippocampus by 12 months of age (Hascup *et al.* 2019). These data support that subregion specific changes to hippocampal glutamate neurotransmission is altered as a function of AD progression. Therefore, targeting the glutamatergic system, specifically by decreasing glutamate release, increasing glutamate clearance, or both, during the prodromal phase may alter disease outcome. Recent studies have shown that riluzole is effective at treating early life stress-induced cognitive decline and

synaptic impairments (Lesuis *et al.* 2019), protects against age-related synaptic alterations related to memory loss (Pereira *et al.* 2014), and is effective at treating depression in pre-clinical models (Banar *et al.* 2010). Further, chronic riluzole treatment reverses gene expression changes observed in microglia, astrocytes, and neurons, and improves memory and pathology in a model of early-onset AD (Okamoto *et al.* 2018). Previous studies have also shown the restoration of glutamatergic neurotransmission with chronic riluzole treatment in a tau model of AD (Hunsberger *et al.* 2015). As such, riluzole is an ideal candidate for early therapeutic intervention for AD. However, it is unknown if riluzole has long-term glutamate modulating or procognitive effects. Therefore, we aimed to determine the long-term therapeutic benefits of prodromal riluzole treatment in the A β PP/PS1 mouse model of progressive amyloidosis.

Due to the general lack of success of AD treatments that begin after noticeable onset of cognitive decline our treatment strategy was aimed at early intervention through restoration of glutamatergic signaling prior to cognitive decline. We used riluzole as a prodromal treatment that has the potential alter AD outcome if administered at the earliest signs of altered glutamatergic neurotransmission. The A β PP/PS1 mouse model of AD that we use in the proposal are cognitively normal, lack AD neuropathology, but have elevated glutamate release at 2-4 months of age, begin showing cognitive decline and A β plaque accumulation at approximately 6-8 months of age, and have advanced AD neuropathology and are cognitively impaired at 10-12 months. The early four month Riluzole treatment (2-6 months of age) allowed us to complete administration targeting these early changes in glutamatergic neurotransmission prior to measurable cognitive decline in this AD model. The interval between treatment cessation and initiation of cognitive testing allowed us to take advantage of cognitive differences observed at 12 months of age while also examining potential long-term benefits of early intervention aimed at restoring glutamatergic neurotransmission, thereby delaying and/or preventing AD-related cognitive decline.

Consistent with our previous work, glutamatergic dysfunction and decreased cognition were observed in A β PP/PS1 vehicle-treated mice at 12 months of age (Hascup *et al.* 2019; Hascup *et al.* 2018). Here, we built on that knowledge and show that both basal glutamate and evoked glutamate release are elevated at this time point, supporting alterations to the glutamatergic neurotransmission are in flux as a result of disease progression. Prodromal riluzole treatment from (2-6 months of age), followed by six months without treatment, rescued basal glutamate and evoked glutamate release in

12-month-old A β PP/PS1 mice to levels consistent with those observed in vehicle-treated normal aging C57BL/6 control mice. A β PP/PS1 riluzole-treated mice also had improved spatial learning and memory performance compared to vehicle-treated genotype-matched mice, indicating that riluzole may have long-term procognitive benefits.

Since we did not observe long-term effects on glutamate neurotransmission or cognition with LY379268 administration under a similar treatment regimen (Hascup *et al.* 2019), it is unlikely that these effects were mediated through metabotropic glutamate receptor 2/3. Current literature would support a multi-part mechanism to inhibit presynaptic glutamate release and prevent overstimulation of the glutamatergic synapse (Bellingham and Walmsley 1999; Bellingham 2011; Ireland *et al.* 2004; Wang *et al.* 2004). Based on our previous characterizations of glutamatergic neurotransmission during the prodromal period in A β PP/PS1 mice (Hascup and Hascup 2015; Hascup *et al.* 2019), inhibition of neuronal excitation during this time should be the most advantageous in preventing subsequent neuronal damage and cognitive decline. However, Hunsberger *et al.* (2015) demonstrated that riluzole may also be efficacious later in disease progression as it was shown to effectively mediate elevated glutamate neurotransmission in a tau model of AD. Since hyperphosphorylated tau is typically observed later in disease progression, the neuropathological profile for each patient may need to be considered for optimal treatment efficacy.

Previous data support a decrease in GFAP immunoreactivity with riluzole treatment (Carbone *et al.* 2012b; Fumagalli *et al.* 2006). In this study, we observed astrocyte clustering around amyloid plaques which has been previously noted (Hascup *et al.* 2018; Carbone *et al.* 2012b), but no differences in GFAP mean density in any of the hippocampal subregions with riluzole treatment. The inability of riluzole to reduce GFAP immunoreactivity in this model could possibly be due to the retention of plaque load regardless of treatment. Continuation of plaque accumulation throughout disease progression results in a chronic inflammatory response (Olabarria *et al.* 2010; Hascup *et al.* 2018; Findley *et al.* 2019) that riluzole treatment does not attenuate. Further, we cannot rule out a role of soluble A β in chronic inflammation. But, the reported changes in glutamatergic neurotransmission across treatment groups was not a result of α 7nAChR expression differences that could have affected soluble A β ₄₂-mediated stimulation.

Overall, the results of this study support the use of riluzole as an early therapeutic intervention strategy to ameliorate cognitive decline and restore glutamatergic tone. Additional studies are ongoing to elucidate riluzole's mechanism of action in this AD model that includes presynaptic and postsynaptic modifications of glutamatergic signaling as well as any sex differences in glutamate-related pathology and response to riluzole treatment.

--Human subjects --

Involves human subjects:

If yes: Informed consent & ethics approval achieved:

=> if yes, please ensure that the info "Informed consent was achieved for all subjects, and the experiments were approved by the local ethics committee." is included in the Methods.

ARRIVE guidelines have been followed:

Yes

=> if it is a Review or Editorial, skip complete sentence => if No, include a statement in the "Conflict of interest disclosure" section: "ARRIVE guidelines were not followed for the following reason:

"

(edit phrasing to form a complete sentence as necessary).

=> if Yes, insert in the "Conflict of interest disclosure" section:

"All experiments were conducted in compliance with the ARRIVE guidelines." unless it is a Review or Editorial

Acknowledgements

This work was supported by the National Institutes of Health [NIA R01AG057767 and NIA R01AG061937], the SIU Foundation at the School of Medicine [Harriss and Fannie Belle Roe Malan Research Endowment and the Illinois Health Improvement Association Research Endowment], the Center for Alzheimer's Disease and Related Disorders, the Kenneth Stark Endowment, and the William E. McElroy Foundation.

Author Contributions:

KNH conceived the study, conducted the experiments, analyzed the data, and wrote the manuscript. CAF performed plaque analysis, assisted with immunofluorescence imaging, and assisted in writing the manuscript. JB and CAF performed the immunofluorescence and corresponding data analysis and revised the manuscript. SOB performed MWM. KD assisted with statistical interpretation of the data analysis. ST supervised immunofluorescence and revised the manuscript. AB revised the manuscript. ERH conceived and supervised the study and revised the manuscript. All authors approved the final version of the manuscript.

Conflict of Interest

The authors declare no conflicts of interest.

References

- Banasr M., Chowdhury G. M. I., Terwilliger R., Newton S. S., Duman R. S., Behar K. L., Sanacora G. (2010) Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. *Mol. Psychiatry* **15**, 501–11.
- Bellingham M. C. (2011) A Review of the Neural Mechanisms of Action and Clinical Efficiency of Riluzole in Treating Amyotrophic Lateral Sclerosis: What have we Learned in the Last Decade? *CNS Neurosci. Ther.* **17**, 4–31.
- Bellingham M. C., Walmsley B. (1999) A Novel Presynaptic Inhibitory Mechanism Underlies Paired Pulse Depression at a Fast Central Synapse. *Neuron* **23**, 159–170.
- Bromley-Brits K., Deng Y., Song W. (2011) Morris Water Maze test for learning and memory deficits in Alzheimer's disease model mice. *J. Vis. Exp.* 53, e2920.
- Carbone M., Duty S., Rattray M. (2012a) Riluzole elevates GLT-1 activity and levels in striatal astrocytes. *Neurochem. Int.* **60**, 31–38.
- Carbone M., Duty S., Rattray M. (2012b) Riluzole neuroprotection in a parkinson's disease model involves suppression of reactive astrogliosis but not GLT-1 regulation. *BMC Neurosci.* **13**, 38.
- Chowdhury G. M. I., Banasr M., Graaf R. A. de, Rothman D. L., Behar K. L., Sanacora G. (2008) Chronic Riluzole Treatment Increases Glucose Metabolism in Rat Prefrontal Cortex and Hippocampus. *J. Cereb. Blood Flow Metab.* **28**, 1892–1897.
- Deng Y., Xu Z., Xu B., Tian Y., Xin X., Deng X., Gao J. (2009) The protective effect of riluzole on manganese caused disruption of glutamate-glutamine cycle in rats. *Brain Res.* **1289**, 106–17.
- Erickson J. D. (2017) Functional identification of activity-regulated, high-affinity glutamine transport in hippocampal neurons inhibited by riluzole. *J. Neurochem.* **142**, 29–40.
- Findley C. A., Bartke A., Hascup K. N., Hascup E. R. (2019) Amyloid Beta-Related Alterations to Glutamate Signaling Dynamics During Alzheimer's Disease Progression. *ASN Neuro* **11**, 1–20.
- Frizzo M. E. dos S., Dall'Onder L. P., Dalcin K. B., Souza D. O. (2004) Riluzole enhances glutamate uptake in rat astrocyte cultures. *Cell. Mol. Neurobiol.* **24**, 123–8.

- Fumagalli E., Bigini P., Barbera S., Paola M. De, Mennini T. (2006) Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease. *Exp. Neurol.* **198**, 114–128.
- Fumagalli E., Funicello M., Rauen T., Gobbi M., Mennini T. (2008) Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. *Eur. J. Pharmacol.* **578**, 171–176.
- Godyń J., Jończyk J., Panek D., Barbara M. (2016) Therapeutic strategies for Alzheimer's disease in clinical trials. *Pharmacol. Reports* **68**, 127–138.
- Gourley S. L., Espitia J. W., Sanacora G., Taylor J. R. (2011) Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice. *Psychopharmacology (Berl)*. **219**, 805–814.
- Hascup E. R., Broderick S. O., Russell M. K., Fang Y., Bartke A., Boger H. A., Hascup K. N. (2018) Diet-Induced Insulin Resistance Elevates Hippocampal Glutamate as well as VGLUT1 and GFAP Expression in A β PP/PS1 Mice. *J. Neurochem.*
- Hascup E. R., Wang F., Kopchick J. J., Bartke A. (2015) Inflammatory and Glutamatergic Homeostasis Are Involved in Successful Aging. *J. Gerontol. A. Biol. Sci. Med. Sci.*
- Hascup K. N., Britz J., Findley C. A., Tischkau S., Hascup E. R. (2019) LY379268 Does Not Have Long-Term Procognitive Effects nor Attenuate Glutamatergic Signaling in A β PP/PS1 Mice. *J. Alzheimer's Dis.* **68**, 1193–1209.
- Hascup K. N., Findley C. A., Sime L. N., Hascup E. R. (2020) Hippocampal alterations in glutamatergic signaling during amyloid progression in A β PP/PS1 mice. *Sci. Rep.* **10**, 14503.
- Hascup K. N., Hascup E. R. (2015) Altered neurotransmission prior to cognitive decline in A β PP/PS1 mice, a model of Alzheimer's disease. *J. Alzheimers. Dis.* **44**, 771–6.
- Hascup K. N., Hascup E. R. (2016) Soluble Amyloid- β 42 Stimulates Glutamate Release through Activation of the α 7 Nicotinic Acetylcholine Receptor. *J. Alzheimer's Dis.* **53**, 337–347.
- Hascup K. N., Lynn M. K., Fitzgerald P. J., Randall S., Kopchick J. J., Boger H. A., Bartke A., Hascup E. R. (2016) Enhanced Cognition and Hypoglutamatergic Signaling in a Growth Hormone Receptor Knockout Mouse Model of Successful Aging. *J. Gerontol. A. Biol. Sci. Med. Sci.* **72**, 329–337.

- Huijbers W., Mormino E. C., Schultz A. P., Wigman S., Ward A. M., Larvie M., Amariglio R. E., Marshall G. A., Rentz D. M., Johnson K. A., Sperling R. A. (2015) Amyloid- β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. *Brain* **138**, 1023–1035.
- Hunsberger H. C., Weitzner D. S., Rudy C. C., Hickman J. E., Libell E. M., Speer R. R., Gerhardt G. A., Reed M. N. (2015) Riluzole rescues glutamate alterations, cognitive deficits, and tau pathology associated with P301L tau expression. *J. Neurochem.* **135**, 381–394.
- Ireland M. F., Noakes P. G., Bellingham M. C. (2004) P2X7-like receptor subunits enhance excitatory synaptic transmission at central synapses by presynaptic mechanisms. *Neuroscience* **128**, 269–280.
- Ishiyama T., Okada R., Nishibe H., Mitsumoto H., Nakayama C. (2004) Riluzole slows the progression of neuromuscular dysfunction in the wobbler mouse motor neuron disease. *Brain Res.* **1019**, 226–36.
- Jack C. R., Knopman D. S., Jagust W. J., Petersen R. C., Weiner M. W., Aisen P. S., Shaw L. M., Vemuri P., Wiste H. J., Weigand S. D., Lesnick T. G., Pankratz V. S., Donohue M. C., Trojanowski J. Q. (2013) Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *Lancet. Neurol.* **12**, 207–16.
- Lesuis S. L., Kaplick P. M., Lucassen P. J., Krugers H. J. (2019) Treatment with the glutamate modulator riluzole prevents early life stress-induced cognitive deficits and impairments in synaptic plasticity in APP^{swe}/PS1^{dE9} mice. *Neuropharmacology* **150**, 175–183.
- Miller S. L., Fenstermacher E., Bates J., Blacker D., Sperling R. A., Dickerson B. C. (2008) Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline. *J. Neurol. Neurosurg. Psychiatry* **79**, 630–5.
- Minkeviciene R., Ihalaenen J., Malm T., Matilainen O., Keksa-Goldsteine V., Goldsteins G., Iivonen H., Leguit N., Glennon J., Koistinaho J., Banerjee P., Tanila H. (2008) Age-related decrease in stimulated glutamate release and vesicular glutamate transporters in APP/PS1 transgenic and wild-type mice. *J. Neurochem.* **105**, 584–94.
- Mota S. I., Ferreira I. L., Rego A. C. (2014) Dysfunctional synapse in Alzheimer's disease – A focus on NMDA receptors. *Neuropharmacology* **76**, 16–26.

- Mura E., Zappettini S., Preda S., Biundo F., Lanni C., Grilli M., Cavallero A., Olivero G., Salamone A., Govoni S., Marchi M. (2012) Dual effect of beta-amyloid on $\alpha 7$ and $\alpha 4\beta 2$ nicotinic receptors controlling the release of glutamate, aspartate and GABA in rat hippocampus. *PLoS One* **7**, e29661.
- Nishio T., Taura K., Iwaisako K., Koyama Y., Tanabe K., Yamamoto G., Okuda Y., Ikeno Y., Yoshino K., Kasai Y., Okuno M., Seo S., Sakurai T., Asagiri M., Hatano E., Uemoto S. (2017) Hepatic vagus nerve regulates Kupffer cell activation via $\alpha 7$ nicotinic acetylcholine receptor in nonalcoholic steatohepatitis. *J. Gastroenterol.* **52**, 965–976.
- O'Brien J. L., O'Keefe K. M., LaViolette P. S., DeLuca A. N., Blacker D., Dickerson B. C., Sperling R. A. (2010) Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. *Neurology* **74**, 1969–76.
- Okamoto M., Gray J. D., Larson C. S., Kazim S. F., Soya H., McEwen B. S., Pereira A. C. (2018) Riluzole reduces amyloid beta pathology, improves memory, and restores gene expression changes in a transgenic mouse model of early-onset Alzheimer's disease. *Transl. Psychiatry* **8**, 153.
- Okonkwo O. C., Oh J. M., Kosciak R., Jonaitis E., Cleary C. A., Dowling N. M., Bendlin B. B., Larue A., Hermann B. P., Barnhart T. E., Murali D., Rowley H. A., Carlsson C. M., Gallagher C. L., Asthana S., Sager M. A., Christian B. T., Johnson S. C. (2014) Amyloid burden, neuronal function, and cognitive decline in middle-aged adults at risk for Alzheimer's disease. *J. Int. Neuropsychol. Soc.* **20**, 422–33.
- Olabarria M., Noristani H. N., Verkhatsky A., Rodríguez J. J. (2010) Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease. *Glia* **58**, 831–838.
- Olney J. W., Wozniak D. F., Farber N. B. (1997) Excitotoxic neurodegeneration in Alzheimer disease. New hypothesis and new therapeutic strategies. *Arch. Neurol.* **54**, 1234–40.
- Parameshwaran K., Dhanasekaran M., Suppiramaniam V. (2008) *Amyloid beta peptides and glutamatergic synaptic dysregulation*.
- Parsons C. G., Stöfler A., Danysz W. (2007) Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. *Neuropharmacology* **53**, 699–723.

Paula-Lima A. C., Brito-Moreira J., Ferreira S. T. (2013) Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease. *J. Neurochem.* **126**, 191–202.

Paxinos G., Franklin K. B. J. (2004) *The Mouse Brain in Stereotaxic Coordinates*. Gulf Professional Publishing.

Pereira A. C., Lambert H. K., Grossman Y. S., Dumitriu D., Waldman R., Jannetty S. K., Calakos K., Janssen W. G., McEwen B. S., Morrison J. H. (2014) Glutamatergic regulation prevents hippocampal-dependent age-related cognitive decline through dendritic spine clustering. *Proc. Natl. Acad. Sci. U. S. A.* **111**, 18733–8.

Ren S. C., Shao H., Ji W. G., Jiang H. H., Xu F., Chen P. Z., Mi Z., Wen B., Zhu G. X., Zhu Z. R. (2015) Riluzole prevents soluble A β 1-42 oligomers-induced perturbation of spontaneous discharge in the hippocampal CA1 region of rats. *Amyloid* **22**, 36–44.

Talantova M., Sanz-Blasco S., Zhang X., Xia P., Akhtar M. W., Okamoto S., Dziewczapolski G., Nakamura T., Cao G., Pratt A. E., Kang Y.-J., Tu S., Molokanova E., McKercher S. R., Hires S. A., Sason H., Stouffer D. G., Buczynski M. W., Solomon J. P., Michael S., Powers E. T., Kelly J. W., Roberts A., Tong G., Fang-Newmeyer T., Parker J., Holland E. A., Zhang D., Nakanishi N., Chen H.-S. V., Wolosker H., Wang Y., Parsons L. H., Ambasudhan R., Masliah E., Heinemann S. F., Piña-Crespo J. C., Lipton S. A. (2013) A β induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. *Proc. Natl. Acad. Sci. U. S. A.* **110**, E2518-27.

Wang S. J., Wang K. Y., Wang W. C. (2004) Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes). *Neuroscience* **125**, 191–201.

Webster S. J., Bachstetter A. D., Nelson P. T., Schmitt F. A., Eldik L. J. Van (2014) Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. *Front. Genet.* **5**, 1–14.

Winblad B., Poritis N. (1999) Memantine in severe dementia: results of the 9M-best study (benefit and efficacy in severely demented patients during treatment with memantine). *Int. J. Geriatr. Psychiatry* **14**, 135–146.

Yang T., Li S., Xu H., Walsh D. M., Selkoe D. J. (2017) Large Soluble Oligomers of Amyloid β -

Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate. *J. Neurosci.* **37**, 152–163.

Yang Y., Ji W., Zhang Y., Zhou L., Chen H., Yang N., Zhu Z. (2020) Riluzole ameliorates soluble A β 1–42-induced impairments in spatial memory by modulating the glutamatergic/GABAergic balance in the dentate gyrus. *Prog. Neuro-Psychopharmacology Biol. Psychiatry*, 110077.

Figure 1: Experimental Design

An outline of the experimental design. Riluzole treatment was conducted when mice were 2-6 months of age. At 6 months of age, treatment was discontinued and mice were returned to untreated water for the remainder of the study. Animal numbers are located underneath each analysis. *One C57BL/6J vehicle treated mouse died due to complications from anesthetized surgical procedures. #One C57BL/6J vehicle treated and two A β PP/PS1 mice were excluded from immunofluorescent analysis because of inadequate slice preparation and staining procedures. Abbreviations: Morris water maze (MWM).

Figure 2: MWM Training and Probe Challenge

Mice were trained to locate a hidden escape platform over five consecutive days. Each training day consisted of three trials that were averaged into a single data point for each treatment group to analyze swimming speed (A) CIPL (B) and cumulative distance (C). CIPL adjusts for average swim speed and corrects the difference in distance between different start positions and distance to the platform. Representative track plots of the 60 s probe challenge are shown for each treatment group (D). No differences in swimming speed were observed during the probe challenge (E) indicating motor performance does not account for differences in cognitive measurements. C57BL/6J vehicle and A β PP/PS1 riluzole mice, but not A β PP/PS1 vehicle mice, selectively searched the target quadrant compared to the other quadrants for the former location of the hidden escape platform (F). A β PP/PS1 vehicle mice entered the annulus 40 (immediate area surrounding the platform) fewer times compared to C57BL/6J vehicle and A β PP/PS1 riluzole mice (G). N= number of mice. Figures A-C: two-way ANOVA, Dunnett's post-hoc; Figures E-G: one-way ANOVA, Dunnett's post-hoc; *p<0.05, **p<0.01, A β PP/PS1 vehicle (n=12) vs C57BL/6J vehicle mice (n=14); §§p<0.01, §§§p<0.001 A β PP/PS1 vehicle vs A β PP/PS1 riluzole mice (n=11).

Figure 3: Representative Glutamate Traces and Glutamate Measures

A) Representative traces of basal glutamate and stimulus-evoked glutamate release from 70 mM KCl stimulation. Treatment groups are placed into columns and hippocampal subfields are shown in rows. The inset trace at the top of each panel displays the reproducibility of glutamate release and clearance, while the single response is a magnified view of the first inset signal to give a clearer presentation of dynamics of glutamatergic signaling. Concentration and time axes are consistent in all panels for comparisons. B) Basal glutamate was determined prior to local application of 70 mM KCl in each hippocampal subfield. C) The volume of stimulus ejected was consistent across treatment groups for direct comparisons of evoked glutamate release. D) The average glutamate

release was determined by subtracting the peak amplitude from the basal measure obtained prior to each ejection of the stimulus. E) Glutamate uptake rate was calculated by multiplying the peak response (μM) by logarithmic slope (k_{-1}) of glutamate decay versus time (s^{-1}) as estimated by the use of regression analysis ($R^2 \geq 0.9$). N= number of mice. A one-way ANOVA with Dunnett's post-hoc was used in each hippocampal subfield. * $p < 0.05$; ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$ A β PP/PS1 vehicle (11-12) versus C57BL/6J vehicle (n=12-13) mice; § $p < 0.05$, §§ $p < 0.01$, §§§ $p < 0.001$, §§§§ $p < 0.0001$ A β PP/PS1 vehicle versus A β PP/PS1 riluzole (n=11) mice.

Figure 4: Hippocampal $\alpha 7\text{nAChR}$ Expression

A) Representative 40x images (scale bar = 20 μM) of DAPI (blue) and $\alpha 7\text{nAChR}$ (red) expression in the DG (A-C), CA3 (D-F), and CA1 (G-I) for the three treatment groups separated into columns. The average mean $\alpha 7\text{nAChR}$ staining density is shown in J. A one-way ANOVA with Dunnett's post-hoc was used in each hippocampal subfield. N= number of mice; C57BL/6J vehicle (n=13), A β PP/PS1 vehicle (n=12); A β PP/PS1 riluzole (n=9) mice.

Figure 5: Hippocampal GFAP/A β Expression

A) Representative 10x images (Scale bar = 100 μM) of GFAP (red) and A β plaque (blue) expression, with 40X insets (scale bar = 20 μm), in the DG (A-C) and CA1/CA3 (D-F) hippocampal subregions for the three treatment groups (columns). Subregion specific changes in GFAP expression (G) was compared using a one-way ANOVA with Dunnett's post-hoc, while a t-test was used for comparing plaque accumulation between riluzole and vehicle treated A β PP/PS1 groups (H). N= number of mice.


Table 1

Treatment Group	Mouse Weight Percent Change (Mean $\pm$ SEM)				
	3 Months	4 Months	5 Months	6 Months	12 Months
C57BL/6J Vehicle	8.5 $\pm$ 0.7	14.0 $\pm$ 0.9	18.13 $\pm$ 1.5	17.9 $\pm$ 2.7	36.2 $\pm$ 1.9
A β PP/PS1 Vehicle	7.0 $\pm$ 1.1	12.2 $\pm$ 2.8	16.3 $\pm$ 3.3	16.6 $\pm$ 3.4	39.7 $\pm$ 3.5
A β PP/PS1 Riluzole	8.2 $\pm$ 0.7	13.2 $\pm$ 1.0	18.4 $\pm$ 1.8	21.7 $\pm$ 1.8	39.9 $\pm$ 2.6


Average percent change of mouse weight during the 4 months of riluzole treatment (3-6 months of age) and at the time of testing (12 months of age).

Supplemental Figure 1: $\alpha 7$ nAChR Primary Antibody with Blocking Peptide


Representative 40x images (scale bar = 20 μ m) from the DG (A), CA3 (B), and CA1) hippocampal subregions showing $\alpha 7$ nAChR primary antibody specificity. Per the manufacturer's recommendations, the rabbit polyclonal $\alpha 7$ nAChR antibody (Alomone Labs; 1:200) was incubated with its associated blocking peptide (at a 1:10 ratio) for 30 minutes at room temperature. This blocking peptide $\alpha 7$ nAChR primary antibody mixture was applied to mouse hippocampal sections as described in the methods section.





jnc_15224_f1.png



jnc_15224_f2.png







jnc_15224_f5.png